These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12408733)

  • 1. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.
    Bass DM; Prevo M; Waxman DS
    Drug Saf; 2002; 25(14):1021-33. PubMed ID: 12408733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral drug formulations. Their potential in modulating adverse effects.
    Florence AT; Jani PU
    Drug Saf; 1994 Mar; 10(3):233-66. PubMed ID: 8043223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.
    Conley R; Gupta SK; Sathyan G
    Curr Med Res Opin; 2006 Oct; 22(10):1879-92. PubMed ID: 17022845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk in esophageal obstruction with slow-release medications.
    Simko V; Joseph D; Michael S
    J Assoc Acad Minor Phys; 1997; 8(2):38-42. PubMed ID: 9167415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release nifedipine bezoar identified one year after discontinuation.
    Niezabitowski LM; Nguyen BN; Gums JG
    Ann Pharmacother; 2000; 34(7-8):862-4. PubMed ID: 10928396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
    Kwong WJ; Diels J; Kavanagh S
    Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.
    Curtis JR; Perez-Gutthann S; Suissa S; Napalkov P; Singh N; Thompson L; Porter-Brown B;
    Semin Arthritis Rheum; 2015 Feb; 44(4):381-8. PubMed ID: 25300699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-situ monitoring of in vitro drug release processes in tablets using optical coherence tomography.
    Wolfgang M; Baniček T; Paudel A; Gruber-Woelfler H; Spoerk M; Kushwah V; Khinast JG
    J Pharm Biomed Anal; 2024 Sep; 247():116258. PubMed ID: 38830272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling drug effects through improved oral formulations. The pharmacokinetics of the prazosin gastrointestinal therapeutic system.
    DiPiro JT
    Am J Med; 1989 Aug; 87(2A):31S-35S. PubMed ID: 2764016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin extended release: metformin gastric retention, metformin GR, metformin XR.
    Drugs R D; 2005; 6(5):316-9. PubMed ID: 16128603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.